Macrogenics Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (45)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Macrogenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Macrogenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Macrogenics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Macrogenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Macrogenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Macrogenics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Macrogenics

  1.1 Business Overview

  1.2 Macrogenics Pipeline Overview

 

2. Macrogenics Cancer Drugs in Preclinical Phase

  2.1 Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

  2.2 antibody drug conjugates - MacroGenics

  2.3 MGA 012

 

3. Macrogenics Cancer Drugs in Clinical Phase

  3.1 Enoblituzumab Companion Diagnostic - ImaginAb

 

4. Macrogenics Cancer Drugs in Phase-I

  4.1 JNJ 64052781

  4.2 Enoblituzumab

  4.3 MGD 006

  4.4 PF 6671008

  4.5 MGD 009

  4.6 MGD 007

 

5. Macrogenics Cancer Drugs in Phase-III

  5.1 Margetuximab

 

6. No development Reported in Cancer Drug in Clinical Pipeline

  6.1 Stem Cell Antibodies - Bioprocessing Technology Institute/Raven biotechnologies

  6.2 Bispecific Antibody Therapeutics - MacroGenics/Servier

 

7. Discontinued in Cancer Drug in Clinical Pipeline

  7.1 Immunotherapeutics - MacroGenics

  7.2 RAV 12

  7.3 Anti-CD3 Clinical Imaging - ImaginAb/MacroGenics

  7.4 Anti-CD32B Monoclonal Antibodies - MacroGenics

  7.5 Anticancer Monoclonal Antibodies - Abbott/Raven

  7.6 Human Monoclonal Antibodies - ImmunoGen/Raven

  7.7 Human Monoclonal Antibodies - Medarex/Raven

  7.8 Anticancer Monoclonal Antibodies - Raven Biotechnologies/Wyeth


Figure 1-1: Macrogenics Cancer Pipeline by Phase (%)

Figure 1-2: Macrogenics Cancer Pipeline by Phase (Number)

Figure 1-3: Macrogenics Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Macrogenics Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)